Literature DB >> 17113868

CHO glycosylation mutants: proteoglycans.

Lijuan Zhang1, Roger Lawrence, Beth A Frazier, Jeffrey D Esko.   

Abstract

Most glycosaminoglycan (GAG)-defective mutants have been isolated and characterized from Chinese hamster ovary (CHO) cells. Wild-type and GAG-defective CHO cells have been used by several hundreds of laboratories to study how altering the GAG structure of proteoglycans affects fundamental properties of cells, such as bacterial/viral infection, signaling, protein degradation, and cell adhesion. This chapter describes methods used to construct and characterize new CHO cell lines with gain-of-function GAG structures. These novel CHO cell lines allow herpes simplex virus (HSV) entry or have anticoagulant properties that are not possessed by wild-type CHO cells. The method used to study GAG biosynthetic mechanisms that control specific GAG sequence assembly is also described.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17113868     DOI: 10.1016/S0076-6879(06)16013-9

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  30 in total

1.  Chemokine cooperativity is caused by competitive glycosaminoglycan binding.

Authors:  Guido J R Zaman; Martine J Smit; Folkert Verkaar; Jody van Offenbeek; Miranda M C van der Lee; Lambertus H C J van Lith; Anne O Watts; Angelique L W M M Rops; David C Aguilar; Joshua J Ziarek; Johan van der Vlag; Tracy M Handel; Brian F Volkman; Amanda E I Proudfoot; Henry F Vischer
Journal:  J Immunol       Date:  2014-03-17       Impact factor: 5.422

2.  Changes in glycosaminoglycan structure on differentiation of human embryonic stem cells towards mesoderm and endoderm lineages.

Authors:  Leyla Gasimli; Anne Marie Hickey; Bo Yang; Guoyun Li; Mitche dela Rosa; Alison V Nairn; Michael J Kulik; Jonathan S Dordick; Kelley W Moremen; Stephen Dalton; Robert J Linhardt
Journal:  Biochim Biophys Acta       Date:  2014-01-09

Review 3.  Engineering of routes to heparin and related polysaccharides.

Authors:  Ujjwal Bhaskar; Eric Sterner; Anne Marie Hickey; Akihiro Onishi; Fuming Zhang; Jonathan S Dordick; Robert J Linhardt
Journal:  Appl Microbiol Biotechnol       Date:  2011-11-03       Impact factor: 4.813

4.  Two glycosaminoglycan-binding domains of the mouse cytomegalovirus-encoded chemokine MCK-2 are critical for oligomerization of the full-length protein.

Authors:  Sergio M Pontejo; Philip M Murphy
Journal:  J Biol Chem       Date:  2017-04-21       Impact factor: 5.157

5.  Modulation of heparan sulfate biosynthesis by sodium butyrate in recombinant CHO cells.

Authors:  Payel Datta; Bo Yang; Robert J Linhardt; Susan T Sharfstein
Journal:  Cytotechnology       Date:  2014-01-29       Impact factor: 2.058

Review 6.  Properdin: New roles in pattern recognition and target clearance.

Authors:  Claudia Kemper; Dennis E Hourcade
Journal:  Mol Immunol       Date:  2008-08-08       Impact factor: 4.407

7.  Smallpox inhibitor of complement enzymes (SPICE): regulation of complement activation on cells and mechanism of its cellular attachment.

Authors:  M Kathryn Liszewski; Paula Bertram; Marilyn K Leung; Richard Hauhart; Lijuan Zhang; John P Atkinson
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 8.  Recent progress and applications in glycosaminoglycan and heparin research.

Authors:  Tatiana N Laremore; Fuming Zhang; Jonathan S Dordick; Jian Liu; Robert J Linhardt
Journal:  Curr Opin Chem Biol       Date:  2009-09-24       Impact factor: 8.822

9.  The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis.

Authors:  Claudia Kemper; Lynne M Mitchell; Lijuan Zhang; Dennis E Hourcade
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-25       Impact factor: 11.205

10.  The anticancer activity of lytic peptides is inhibited by heparan sulfate on the surface of the tumor cells.

Authors:  Bodil Fadnes; Oystein Rekdal; Lars Uhlin-Hansen
Journal:  BMC Cancer       Date:  2009-06-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.